PrEParing for Controversy: Understanding the Limitations of Pre-exposure Prophylaxis
The history of the HIV/AIDS epidemic is marked by devastating losses and a disease burden that persists to this day. Though slow to emerge, both government policy and pharmaceutical research began to address the epidemic, and the resulting combinations of antiretroviral cocktails and outreach programs have helped make HIV infection a manageable, if inconvenient, chronic condition. In 2012, however, the FDA approved a drug that had the potential to shift both the American and global strategies regarding HIV and AIDS.